David C. Fisher
- Genetics top 0.2%
- Chronic Lymphocytic Leukemia Research 66
- Pathology and Forensic Medicine top 0.2%
- Lymphoma Diagnosis and Treatment 98
- Hematology top 0.5%
- Hematopoietic Stem Cell Transplantation 19
- Immunology top 1%
- Immunodeficiency and Autoimmune Disorders 18
- Immune Cell Function and Interaction 17
- Dermatology top 0.5%
- Cutaneous lymphoproliferative disorders research 25
-
- Viral-associated cancers and disorders 26
- CAR-T cell therapy research 19
David C. Fisher
184 papers receiving 6.1k citations
Peers
Comparison fields: 5 of 134
- Genetics 1.9k
- Pathology and Forensic Medicine 2.9k
- Hematology 1.4k
- Immunology 1.9k
- Dermatology 721
Countries citing papers authored by David C. Fisher
This map shows the geographic impact of David C. Fisher's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David C. Fisher with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David C. Fisher more than expected).
Fields of papers citing papers by David C. Fisher
This network shows the impact of papers produced by David C. Fisher. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David C. Fisher. The network helps show where David C. Fisher may publish in the future.
Co-authorship network
The 25 scholars most cited alongside David C. Fisher, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 1 | |
| 2 | 2024 | 1 | |
| 3 | 2024 | 0 | |
| 4 | 2023 | 8 | |
| 5 | 2023 | 3 | |
| 6 | 2023 | 3 | |
| 7 | 2023 | 2 | |
| 8 | 2019 | 17 | |
| 9 | 2018 | 81 | |
| 10 | 2017 | 4 | |
| 11 | 2017 | 8 | |
| 12 | Initial Results of a Phase Ib Study of Ibrutinib in Combination with Obinutuzumab in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia | 2017 | 1 |
| 13 | 2016 | 227 | |
| 14 | 2015 | 296 | |
| 15 | 2011 | 100 | |
| 16 | 2011 | 64 | |
| 17 | 2010 | 39 | |
| 18 | 2008 | 80 | |
| 19 | 2008 | 26 | |
| 20 | 2002 | 7 |
About David C. Fisher
David C. Fisher is a scholar working on Genetics, Pathology and Forensic Medicine and Hematology, having authored 192 papers that have together received 6.2k indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (98 papers), Chronic Lymphocytic Leukemia Research (66 papers), Viral-associated cancers and disorders (26 papers), Cutaneous lymphoproliferative disorders research (25 papers), Hematopoietic Stem Cell Transplantation (19 papers), CAR-T cell therapy research (19 papers), Immunodeficiency and Autoimmune Disorders (18 papers) and Immune Cell Function and Interaction (17 papers). The work is most often cited by research in Genetics (1.9k citations), Pathology and Forensic Medicine (2.9k citations) and Hematology (1.4k citations). David C. Fisher has collaborated with scholars based in United States, France and United Kingdom. Frequent co-authors include Arnold S. Freedman, Donna Neuberg, Robert J. Soiffer, Jerome Ritz, Peter Mauch, Edwin P. Alyea, Jennifer R. Brown, John G. Gribben, Joseph H. Antin and Corey Cutler. Their work appears in journals such as Journal of Clinical Oncology, Blood and The Journal of Immunology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.